Navigation Links
Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Date:6/17/2010

t (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of RB006 paired with the IV bolus formulation of RB007. REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in late 2010 or early 2011. It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery. REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively). REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy. Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fract
'/>"/>

SOURCE Regado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
2. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
3. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
4. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
5. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
6. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
9. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YORK , Sept. 18, 2014 This BCC Research ... share of major players, market growth and size, and opportunities ... trends and revenue through 2018. Patent analysis in the report ... as the U.S., Europe and ... to: - Define and discuss the global medical device technologies ...
(Date:9/18/2014)... Sept. 18, 2014   Fruit Street Health ... initial seed round of funding. The ... by a series of individual investors, the majority of ... in the initial round are; Houston Cardiology Consultants ... Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
(Date:9/18/2014)... 2014  ADM Tronics Unlimited, Inc. (OTCQB: ADMT) ... its corporate Advisory Board for business development. ... Harvard Medical School and Visiting Professor at the ... Masters degree in Electronics Engineering and his Ph.D. ... Bologna. After spending a year as a visiting ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
... ADDISON, Texas, March 11, 2011 U LURUInc.(NYSE ... the development of a portfolio of wound management and oral ... NYSE Amex LLC (the "Exchange") advising ULURU that it is ... continued listing standards under Section 1003 of the Exchange,s Company ...
... (Nasdaq: NVAX ), a clinical-stage vaccine company, announced ... be presenting at the ROTH 23rd Annual OC Growth Stock ... at The Ritz Carlton, Laguna Niguel, CA.  A live audio-only ... Company website at www.novavax.com under Investors/Events, and a ...
Cached Medicine Technology:ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex 2
(Date:9/19/2014)... 19, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Potassium Chloride . , ... recalled one lot of Potassium Chloride Injection 10mEq ... cartons. Potassium Chloride, administered intravenously, is used to treat potassium ... on a labeling error on the shipping cartons in a ...
(Date:9/19/2014)... Yisrayl Hawkins, Pastor of The House of ... need to protect children. He begins by encouraging the reader ... reminds that there are many other children, like Michael Brown, ... spreading faster than cancer all over the world and must ... to seven billion Michaels in the world who were left ...
(Date:9/19/2014)... VogueQueen.com has recently unveiled a ... ladies more beautiful at their weddings. The new range ... The company’s new products are made for the coming ... for all the global clients. , “The ... have ordered several items on its website. I'm very ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Defendants ... http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s Philadelphia Court ... claims filed on behalf of out-of-state plaintiffs dismissed, ... on September 11th, the defendants maintain that circumstances ... in the lawsuits have no connection to Pennsylvania. ...
(Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
Breaking Medicine News(10 mins):Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Yisrayl Hawkins Says the Michael Brown Scenario Will Continue Without Swift Action in New Post 2Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2
... , 221.10.254.64 (Garrison, NY) Concern about the capacity ... studies has largely focused on impairment due to psychotic ... given to the cognitive errors that prospective participants make ... In a study reported in IRB: ...
... HealthDay Reporter , MONDAY, Aug. 8 (HealthDay ... say that elderly lung cancer patients can gain significant ... in younger patients. The finding raises questions about ... American Society of Clinical Oncology in 2004, which advised ...
... There are increasing pressures for health care providers ... policy making. But Canadians are more likely to allow ... that their privacy is protected. A new report by ... Electronic Health Information at the University of Ottawa and ...
... Aug. 8 (HealthDay News) -- One reason why people worldwide ... be because the games allow them to "try on" characteristics ... The research included hundreds of casual game players and nearly ... for playing, as well as their post-game emotions. The ...
... HealthDay Reporter , MONDAY, Aug. 8 (HealthDay News) -- At ... diagnose heart disease is found to have major blockages requiring ... few are found to have a major blockage when undergoing ... procedures, according to a study in the Aug. 16 issue ...
... published in the August issue of the Journal of ... in the number of laparoscopic bariatric procedures, an increase in ... mortality rates between 2003 and 2008. During the past decade, ... authors concluded that these trends are due, in part, to ...
Cached Medicine News:Health News:Schizophrenia study finds cognitive deficits significantly impair decision-making capacity 2Health News:Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study 2Health News:Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study 3Health News:Most Canadians can be uniquely identified from their date of birth and postal code 2Health News:Hospitals Vary Widely in Rate of Heart Procedures: Study 2Health News:Hospitals Vary Widely in Rate of Heart Procedures: Study 3Health News:Number of laparoscopic bariatric procedures continued to rise between 2003-2008 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: